Braveheart Bio Incorporation

Chart
Good to know: Investing in stocks tends to provide long-term positive returns, but it also involves risks. You can lose some or all of your investment. Past performance of this stock is not a reliable indicator of future results. Data from external providers has not been altered by Saxo. See full data disclaimer.
Quotes
- Bid
- Ask
- Open
- Previous close
- Volume
- Relative volume
- High
- Low
Returns
Key stats
Analyst consensus
ESG risk
ESG risk is a measure of how well a company manages material ESG risks. Sustainalytics’ ESG risk category is designed to help investors identify and understand financially material ESG risks at the company level and how they might affect the long-term performance for equity investments. The scale is from 0-100. The lower the risk, the better (0 is equivalent to no risk and 100 the most severe).
Download ESG risk methodology (PDF)Financials
About Braveheart Bio Incorporation
Braveheart Bio Inc is a clinical-stage biotechnology company focused on developing therapeutics to treat hypertrophic cardiomyopathy (HCM) and other cardiovascular diseases. Its flagship product candidate, BHB-1893, is an oral small-molecule cardiac myosin inhibitor being developed for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM).
Others were interested in
Frequently asked questions
To buy Braveheart Bio Incorporation stock, open a Saxo account and fund it. With SaxoInvestor or SaxoTrader, you can easily search for Braveheart Bio Incorporation by name or ticker, choose the number of shares, and place your order.
The ticker symbol for Braveheart Bio Incorporation is BRVE. You can use this code to quickly find the stock in Saxo’s platforms and track its price and performance.
Braveheart Bio Incorporation has its primary listing on NASDAQ. You can trade Braveheart Bio Incorporation with a Saxo account, alongside thousands of other stocks worldwide.
Yes, Braveheart Bio Incorporation is available to trade on SaxoInvestor and SaxoTrader. You can buy shares directly and include Braveheart Bio Incorporation as part of a broader investment portfolio.